Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

Clinical Imetelstat: MDS

All Publications

Patient-Reported Outcomes Among Heavily Pretreated Patients With Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated With Imetelstat in IMerge

Clinical Imetelstat: MDS Imetelstat

Winter Heme 2024

Sekeres, et. al.

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence Across Different Risk Subgroups in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents in IMerge Phase 3 Study

Clinical Imetelstat: MDS Imetelstat

Komrokji, et. al.

Impact of Mutational Status on Clinical Response to Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Clinical Imetelstat: MDS Imetelstat

Santini, et. al.

Durable Continuous Transfusion Independence (TI) With Imetelstat in IMerge Phase 3 for Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents

Clinical Imetelstat: MDS Imetelstat

Platzbecker, et. al.

Imetelstat in patients with lower-risk MDS who have relapsed or are refractory to erythropoiesis-stimulating agents in IMerge phase 3 trial

Clinical Imetelstat: MDS Imetelstat

The Lancet 2023

Platzbecker, et. al.

Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat versus Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible to Erythropoiesis Stimulating Agents

Clinical Imetelstat: MDS Imetelstat

AMCP Nexus 2023

Sekeres, et. al.

Telomerase-targeted therapies in myeloid malignancies

Clinical Imetelstat: MDS Imetelstat Non-clinical Imetelstat Non-clinical Imetelstat: MF

Blood Advances 2023

Waksal, et. al.

Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents

Clinical Imetelstat: MDS Imetelstat

Sekeres, et. al

Disease Modifying Activity of Imetelstat in Patients with Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

Clinical Imetelstat: MDS Imetelstat

Santini, et. al

Continuous Transfusion Independence with Imetelstat in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

Clinical Imetelstat: MDS Imetelstat

Platzbecker, et. al.

[facetwp facet="publication_load_more"]